腹腔镜肝切除术治疗肝细胞癌中国专家共识(2020版)

2020-11-30 中国研究型医院学会 中华消化外科杂志.2020.19(11):1119-1134.

虽然腹腔镜肝切除术(LH)治疗肝癌患者数量呈明显增多趋势,但在临床推广应用过程中仍存在适应证掌控不严,术前评估、手术操作及术后随访等环节欠规范的问题。因此,《腹腔镜肝切除术治疗肝细胞癌中国专家共识(2

中文标题:

腹腔镜肝切除术治疗肝细胞癌中国专家共识(2020版)

发布机构:

中国研究型医院学会

发布日期:

2020-11-30

简要介绍:

虽然腹腔镜肝切除术(LH)治疗肝癌患者数量呈明显增多趋势,但在临床推广应用过程中仍存在适应证掌控不严,术前评估、手术操作及术后随访等环节欠规范的问题。因此,《腹腔镜肝切除术治疗肝细胞癌中国专家共识(2020版)》,从肝癌腹腔镜外科治疗的适应证选择、手术入路、操作流程、技术要点、并发症防控等重要环节进行探讨总结,并对关键争议热点进行讨论,形成指导性推荐建议,旨在指导临床医师在肝癌的腹腔镜外科治疗中做出合理决策。因此,在面对患者时应在充分了解肝癌治疗的最佳临床证据、考虑患者病情及意愿的基础上,根据术者及团队的腹腔镜技术水平、专业经验及可利用的医疗资源,制订合理的手术方案。

 

下载附件:

(因为版权问题,不支持下载)

评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=969396, encodeId=e43c96939658, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4ec95218311, createdName=14774852m22暂无昵称, createdTime=Sat May 29 10:31:41 CST 2021, time=2021-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919780, encodeId=b67e919e80a9, content=学习了 受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210130/f777d0b91a25425ba588babbf050d6d1/328b4c90fd7741d090ece3b8f155fc70.jpg, createdBy=25525455713, createdName=ms7000000982141651, createdTime=Mon Jan 25 17:52:58 CST 2021, time=2021-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=913260, encodeId=03169132609a, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a97e1895398, createdName=ms3316075004000287, createdTime=Sun Jan 03 11:12:58 CST 2021, time=2021-01-03, status=1, ipAttribution=)]
    2021-05-29 14774852m22暂无昵称

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=969396, encodeId=e43c96939658, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4ec95218311, createdName=14774852m22暂无昵称, createdTime=Sat May 29 10:31:41 CST 2021, time=2021-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919780, encodeId=b67e919e80a9, content=学习了 受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210130/f777d0b91a25425ba588babbf050d6d1/328b4c90fd7741d090ece3b8f155fc70.jpg, createdBy=25525455713, createdName=ms7000000982141651, createdTime=Mon Jan 25 17:52:58 CST 2021, time=2021-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=913260, encodeId=03169132609a, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a97e1895398, createdName=ms3316075004000287, createdTime=Sun Jan 03 11:12:58 CST 2021, time=2021-01-03, status=1, ipAttribution=)]
    2021-01-25 ms7000000982141651

    学习了 受益匪浅

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=969396, encodeId=e43c96939658, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4ec95218311, createdName=14774852m22暂无昵称, createdTime=Sat May 29 10:31:41 CST 2021, time=2021-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=919780, encodeId=b67e919e80a9, content=学习了 受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210130/f777d0b91a25425ba588babbf050d6d1/328b4c90fd7741d090ece3b8f155fc70.jpg, createdBy=25525455713, createdName=ms7000000982141651, createdTime=Mon Jan 25 17:52:58 CST 2021, time=2021-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=913260, encodeId=03169132609a, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a97e1895398, createdName=ms3316075004000287, createdTime=Sun Jan 03 11:12:58 CST 2021, time=2021-01-03, status=1, ipAttribution=)]
    2021-01-03 ms3316075004000287

    学习了

    0

拓展阅读

2013 JSH循证临床实践指南:肝细胞癌-更新版(JSH-HCC指南第3版)

日本肝脏学会(JSH,The Japan Society of Hepatology) · 2015-01-20

肝细胞癌合并门静脉癌栓多学科诊治中国专家共识(2016年版)

全国肝癌合并癌栓诊治研究协作组 · 2016-06-02

肝脏影像报告和数据系统管理工作组肝细胞癌诊断共识意见

美国肝病研究学会(AASLD,American Association for the Study of Liver Diseases) · 2016-06-02

肝细胞癌合并血管侵犯专家共识(讨论稿)

中国医疗保健国际交流促进会 · 2016-06-02

2014年KLCSG-NCC实践指南:肝细胞癌

暂未更新 · 2016-06-03